A fixed-dose combination (FDC) of an antispasmodic (Camylofin) and an analgesic-antipyretic (Paracetamol). Camylofin is a musculotropic antispasmodic with direct action on smooth muscle, while Paracetamol acts centrally to relieve pain and fever. This combination is primarily indicated for the relief of pain associated with smooth muscle spasm in conditions like renal colic, biliary colic, and dysmenorrhea. It is widely used in the Indian market for acute, colicky pain.
Adult: One tablet (Camylofin 50mg + Paracetamol 325mg) every 6-8 hours as needed for pain. Maximum: 3 tablets in 24 hours.
Note: Take with or after food to minimize gastric irritation. Swallow whole with a glass of water. Do not crush or chew. Use for the shortest duration necessary to control symptoms, typically not exceeding 5 days for pain without medical supervision.
Camylofin exerts a direct papaverine-like spasmolytic effect on smooth muscle (intestinal, biliary, urinary, uterine) by inhibiting phosphodiesterase (PDE), leading to increased intracellular cyclic AMP (cAMP). This causes smooth muscle relaxation independent of autonomic innervation. It also possesses weak anticholinergic properties. Paracetamol's exact mechanism is not fully elucidated but is believed to act primarily in the central nervous system (CNS) by inhibiting the cyclooxygenase (COX) pathway, specifically COX-2 and a variant of COX-1 (COX-3), leading to reduced prostaglandin synthesis in the brain. This results in analgesic and antipyretic effects with minimal peripheral anti-inflammatory activity.
Pregnancy: Category C (US FDA). Camylofin: Data insufficient; use only if potential benefit justifies potential fetal risk, especially in first trimester. Paracetamol: Generally considered the analgesic of choice in pregnancy for short-term use at recommended doses. Avoid in third trimester for prolonged use due to potential risk of premature closure of ductus arteriosus (theoretical).
Driving: May cause dizziness, blurred vision, or drowsiness. Patients should not drive or operate machinery until they know how the medication affects them.
| Warfarin/Acenocoumarol | Paracetamol may potentiate anticoagulant effect, increasing INR and bleeding risk, especially with daily use >1.3g. | Major |
| Isoniazid | Increases the formation of the toxic metabolite (NAPQI) of Paracetamol, raising risk of hepatotoxicity. | Major |
| Anticholinergics (e.g., Atropine, Dicyclomine, Tricyclic Antidepressants) | Additive anticholinergic side effects (dry mouth, constipation, urinary retention, blurred vision). | Moderate |
| Metoclopramide/Domperidone | Camylofin may antagonize the prokinetic effect on GI smooth muscle. | Moderate |
| Cholestyramine | Reduces absorption of Paracetamol if taken within 1 hour. | Moderate |
| Alcohol (Chronic, heavy use) | Induces CYP2E1, increasing Paracetamol toxicity risk. Also additive CNS depression. | Major |
| Other Hepatotoxic drugs (e.g., Carbamazepine, Phenytoin, Rifampicin) | Increased risk of Paracetamol-induced liver damage. | Major |
| 5-HT3 Antagonists (e.g., Ondansetron) | Additive risk of constipation. | Minor |
Same composition (Camylofin (50mg) + Paracetamol (325mg)), different brands: